Pharma responding to massive need in respiratory diseases, PhRMA report finds

There are 130 medicines for asthma, allergies and respiratory diseases currently in development, a new report from Pharmaceutical Research and Manufacturers of America (PhRMA) says.

Among these is a potential first-in-class treatment for asthma, a chronic obstructive pulmonary disease(COPD) medicine targeting lung inflammation and a combination therapy for peanut allergies.

The need for these treatments is enormous. Asthma and COPD alone affect the everyday lives of 40 million patients in the USA, while respiratory allergies affect 10% of children under the age of 18.